Taysha Gene Therapies, Inc. TSHA Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Taysha Gene Therapies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Taysha Gene Therapies, Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Taysha Gene Therapies, Inc.'s total equity?
- Taysha Gene Therapies, Inc. (TSHA) reported total equity of $211.94M in Q1 2026.
- How has Taysha Gene Therapies, Inc.'s total equity changed year-over-year?
- Taysha Gene Therapies, Inc.'s total equity increased by 284.9% year-over-year, from $55.06M to $211.94M.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s total equity?
- Over 5 years (2020 to 2025), Taysha Gene Therapies, Inc.'s total equity has grown at a -0.3% compound annual growth rate (CAGR), from $251.3M to $246.94M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.